VEEVA SYSTEMS

Peter Gassner spent years as a senior engineer at Salesforce before leaving in 2007 to start Veeva. His insight was specific: the life sciences industry — pharma, biotech, medical devices — had terrible software.

Legacy systems from SAP and Oracle were designed for manufacturing companies, not drug development. They were slow, hard to customize, and required armies of consultants to configure.

Gassner believed a purpose-built cloud platform for life sciences could displace those legacy systems entirely. He co-founded Veeva with Matthew Wallach, who brought deep pharma industry relationships.

They raised just $7 million in venture funding from Emergence Capital — a remarkably small amount for a company that would eventually be worth over $30 billion. Eli Lilly was one of the first major customers, signing on in 2008.

Veeva charges pharmaceutical and biotech companies annual subscription fees for cloud software. The core products are Veeva CRM (customer relationship management for pharma sales reps), Veeva Vault (a content management platform for clinical and regulatory documents), and a growing suite of development cloud tools for clinical trials and safety reporting.

The customers are some of the most profitable, compliance-obsessed companies on earth — pharma firms cannot afford systems that fail regulatory audits. That makes switching costs enormous and churn rates very low.

Veeva keeps roughly 120% net revenue retention, which means existing customers keep buying more.

Veeva CRM is the original product — a mobile-friendly platform for pharma sales reps to track doctor visits, samples, and interactions. Veeva Vault is a content management system for regulatory submissions, clinical trial documents, and quality records.

Veeva Clinical Data Cloud handles electronic data capture and data management for clinical trials. Veeva Safety handles pharmacovigilance — tracking adverse events for drugs already on the market.

Together these products cover the entire drug development and commercialization lifecycle.

Veeva grew by targeting the most rigorous regulatory environments first — if your software passes FDA audit requirements, it will pass anything. Starting with compliance-heavy workflows in pharma gave Veeva credibility that took competitors years to match.

Gassner also made a deliberate decision to stay in life sciences rather than horizontal SaaS expansion. Every product was designed specifically for pharma and biotech workflows, which meant the software actually fit what customers needed rather than being generic with bolt-on customizations.

Word of mouth in the tight-knit pharma industry did most of the sales work.

Veeva faces a structural challenge: Salesforce, on whose infrastructure it originally ran, eventually became a competitor after launching its own life sciences cloud. Veeva has been migrating customers off Salesforce infrastructure and onto its own proprietary cloud, which is an enormously complex multi-year transition.

There is also growing competition from Oracle and Medidata in clinical cloud software. And converting to a Public Benefit Corporation creates governance complexity — Gassner has built in protections that make it harder for shareholders to force a sale, which some institutional investors do not love.

Veeva raised only $7 million in total venture funding before its 2013 IPO — from Emergence Capital, which specializes in cloud software. That is a remarkably lean raise for a company that would go public at a $4 billion valuation.

The efficiency with which Gassner built the business — generating positive cash flow early and never needing massive capital infusions — is itself part of the Veeva story. Post-IPO, the company has been self-funding through its own cash generation.